Bromocriptine

Bromocriptine is an ergot-derived drug that functions primarily as a dopamine agonist and serotonin antagonist, shifting the ratio of brain chemicals toward DOPA dominance and away from serotonin. 2 Peat identified its core therapeutic action as the suppression of prolactin, a hormone he associated with estrogen excess, water retention, tumor growth, and inhibited progesterone production. 2 He noted that the drug became widely used to treat a massive iatrogenic epidemic of prolactin-secreting pituitary tumors caused by the introduction of oral contraceptives, replacing surgery as the standard of care. 3 Beyond pituitary tumors, Peat observed that bromocriptine’s anti-prolactin and anti-serotonin effects made it relevant for a range of conditions including Cushing's disease, diabetes, and the correction of obesity through improved glucose metabolism. 2

The drug’s metabolic effects are extensive. Dinkov has highlighted that bromocriptine received FDA approval in 2009 to treat type 2 diabetes, largely due to a potent triglyceride- and cholesterol-lowering effect. 4 Peat explained that serotonin interferes with cellular sugar utilization and insulin secretion, so bromocriptine’s anti-serotonin action directly corrects this impairment. 11 He also noted that cocoa naturally contains both bromocriptine and caffeine, though he observed that bromocriptine seems to be more stimulating to the heart than to the brain. 8 Dinkov further linked the drug’s pro-dopamine, anti-prolactin profile to the restoration of sexual function, citing early observations in elderly Parkinson’s patients who regained libido during treatment. 10

Clinically, Peat advised caution with bromocriptine due to the potential for intense reactions, including flushing and low blood pressure, and recommended starting with very low doses. 1 He generally prioritized foundational metabolic support—thyroid, sugar, and nutritional cofactors—over pharmaceutical intervention. 2 When a correspondent reported that a small dose of 0.6 mg resolved severe winter insomnia, Peat acknowledged the result but suggested that the underlying issue involved all hormones regulating energy production, and that bright light, niacinamide, B vitamins, gelatin, sugar, and salt could help maintain energy during darkness. 5 He considered bromocriptine one of several anti-serotonin options, alongside lisuride and ondansetron, for cases of dangerously high prolactin, which he believed should ideally range between 9 and 12 ng/mL. 6 Roddy has noted research suggesting that men with pattern baldness may be more resistant to the anti-stress effects of bromocriptine. 9

Peat situated bromocriptine within a broader biological context where prolactin and serotonin act as central mediators of stress and degeneration. He described how, in migrating salmon, prolactin surges to regulate water balance as the fish move from saltwater to freshwater, a process that parallels the water retention and tissue deterioration seen in estrogen poisoning. 3 He argued that prolactin excess establishes a self-stimulating vicious circle by inhibiting progesterone production, and that all the effects of prolactin excess which respond to an increased DOPA/serotonin ratio can be achieved to some extent by vitamin B6, thyroid, and progesterone. 7 The drug’s ability to suppress prolactin and block serotonin’s metabolic interference made it, in Peat’s view, a corrective agent for a physiology derailed by estrogen, stress, and darkness. 2